Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight
May 23, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 23, 2023 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Clinical Trial Pipeline Analysis of 100+ Companies | NASH Pipeline Report by DelveInsight Nonalcoholic steatohepatitis...
Inventiva publie ses informations financières du 1er trimestre 2023¹ et fait un point sur ses activités
May 16, 2023 16:00 ET
|
INVENTIVA
Au 31 mars 2023, trésorerie et équivalents de trésorerie à 56,3 millions d’euros, dépôt court terme à 0,7 million d’euros2 et dépôt long terme à 9,3 millions d'euros3, contre 86,7 millions d’euros,...
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
May 16, 2023 16:00 ET
|
INVENTIVA
Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million2, and long term deposit at €9.3 million3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million...
Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
May 11, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
May 09, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom abstracts accepted for presentation at EASL,...
ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES
May 01, 2023 17:36 ET
|
Global Liver Institute
Washington, DC, May 01, 2023 (GLOBE NEWSWIRE) -- On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic...
PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES
April 28, 2023 12:22 ET
|
Global Liver Institute
Washington, DC, April 28, 2023 (GLOBE NEWSWIRE) -- Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid...
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
April 18, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2022
March 23, 2023 17:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, Etats-Unis), le 23 mars 2023 – Inventiva (Euronext Paris et Nasdaq : IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement...
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
March 23, 2023 17:00 ET
|
INVENTIVA
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...